PlainMeds provides educational information only. This is not medical advice. Always consult your doctor or pharmacist.

Drug side effects

oxycodone Side Effects

The reactions most often reported to the FDA for oxycodone (also sold as OxyContin, Roxicodone), with demographics, serious outcomes, and reporting trends.

Data updated 2026-05-15

180,422
FAERS reports

Data from the FDA Adverse Event Reporting System (FAERS), 2002 to 2025. A FAERS report records a temporal association, not proof of cause. See our methodology for how figures are compiled and de-duplicated.

The most commonly reported side effects of oxycodone come from 180,422 reports to the FDA, broken down here by frequency, patient demographics, and serious outcomes.

This page analyzes 180,422 reports to the FDA Adverse Event Reporting System (FAERS) for oxycodone (OxyContin): the reactions reported most often, who reported them, serious outcomes such as hospitalization, and year-over-year trends. A FAERS report does not prove the drug caused the effect, and report volume tracks how widely a drug is used, not how likely an effect is for any one person. Educational information, not medical advice.

Total Reports

180,422

Reports Mentioning Death

51,490

28.5% of reports — not proof the medicine caused the death

Hospitalizations

49,832

27.6% of reports

Top Indication

Product Used For Unknown Indication

Most Reported Adverse Reactions

DRUG DEPENDENCE
27,480
PAIN
26,409
DEATH
19,598
OVERDOSE
19,081
TOXICITY TO VARIOUS AGENTS
16,253
EMOTIONAL DISTRESS
15,630
FATIGUE
11,870
NAUSEA
10,630
DRUG WITHDRAWAL SYNDROME
10,451
DIARRHOEA
8,216
DYSPNOEA
7,699
VOMITING
7,490
RASH
7,264
ARTHRALGIA
7,185
DRUG ABUSE
7,150
HEADACHE
7,072
PYREXIA
6,351
CONFUSIONAL STATE
5,967

Who Reports Side Effects

Gender Distribution

Female 77,782 (54%)
Male 66,996 (46%)
Unknown 237

Age Distribution

0-17 2,226 (2%)
18-44 22,101 (25%)
45-64 36,952 (41%)
65-74 17,737 (20%)
75+ 10,600 (12%)

Reporting Trend by Year

2002 2025

Reactions in Death Reports

Top reactions reported in 51,490 reports where death was an outcome. These are voluntarily reported and do not establish causation.

Reaction Reports
DEATH 19,545
TOXICITY TO VARIOUS AGENTS 13,662
OVERDOSE 8,264
DRUG ABUSE 5,138
COMPLETED SUICIDE 3,586
PAIN 2,220
FATIGUE 2,158
DRUG DEPENDENCE 2,137
VOMITING 1,984
RASH 1,913
GENERAL PHYSICAL HEALTH DETERIORATION 1,906
PNEUMONIA 1,880
NAUSEA 1,781
HYPERTENSION 1,776
INFUSION RELATED REACTION 1,759
DIARRHOEA 1,757
RHEUMATOID ARTHRITIS 1,753
SYSTEMIC LUPUS ERYTHEMATOSUS 1,750
TYPE 2 DIABETES MELLITUS 1,748

Reactions in Hospitalization Reports

Top reactions in 49,832 reports where hospitalization was an outcome.

Reaction Reports
PAIN 5,123
FATIGUE 4,805
NAUSEA 4,647
VOMITING 4,119
DIARRHOEA 4,074
DYSPNOEA 4,068
PNEUMONIA 3,998
PYREXIA 3,631
CONFUSIONAL STATE 3,328
ARTHRALGIA 3,299
RASH 3,254
HEADACHE 3,038
ASTHENIA 3,002
MALAISE 2,810
TOXICITY TO VARIOUS AGENTS 2,708
FALL 2,705
GENERAL PHYSICAL HEALTH DETERIORATION 2,705
CONDITION AGGRAVATED 2,701

Compare oxycodone vs abatacept →

What the FAERS Data Reveals About oxycodone Side Effects

The FDA Adverse Event Reporting System (FAERS) contains 180,422 voluntary reports linked to oxycodone and its brand equivalents (OxyContin, Roxicodone), spanning 2002 through 2025. Of those, 51,490 (28.5%) listed death as an outcome and 49,832 (27.6%) involved hospitalization. The most common indication reported alongside adverse events was Product Used For Unknown Indication.

Demographic breakdowns help contextualize who is being exposed to the drug. Of reports with known sex, 54% were female and 46% male; age distribution skews toward 45-64, with 36,952 reports in that bracket. The single most reported reaction is drug dependence with 27,480 submissions, followed by pain and death.

How to read these numbers

FAERS is a signal-detection tool, not a scorecard. Reports are voluntary, and a single case may list multiple suspect drugs, so numbers above should not be read as incidence rates or per-patient risk. Widely prescribed drugs naturally accumulate more reports than niche therapies even when individual risk is low. These aggregates are useful for spotting patterns that merit further pharmacovigilance, not for choosing between medications. This page is for educational reference only and is not medical advice, speak with a licensed clinician about any side-effect concerns.